Polypeptide With Localisation/Targeting Motif TRIZ Cases

Single-cell sequencing and MHC tetramer sorting address heterogeneous TCR recognition to improve CMV target-cell killing.

Target tumor transcription-replication conflicts with DDIAs while protecting engineered immune cells to preserve immune-mediated killing.

Targeted FCGRT editing reduces FcRn–IgG interactions and circulating IgG while preserving albumin half-life in autoimmune disorder treatment.

Engineered cytokine receptor switches promote memory-like CAR T-cell phenotypes, supporting longer T-cell persistence and cancer relapse prevention.

Conventional CPPs move macromolecules across cell membranes but suffer poor tissue selectivity; defined sequences aim to improve delivery with fewer off-target effects.

An HLA-G-specific antibody binds monomers and dimers to block immune suppression and improve immune-cell targeting of cancer cells.

Conventional approaches lack precise intracellular oxygen control; expressed Cld generates oxygen locally while preserving viability.

A fused ALP and membrane-protein polypeptide calibrator enables precise EV-associated ALP measurement without isolating whole extracellular vesicles.

c-Myc-like, SV40, and nucleoplasmin NLS sequences improve CRISPR editing and fetal hemoglobin induction in hematopoietic cells.

Dual B7-H3 VHH binding and CRISPR/Cas9 knockout of TCR and HLA-A improve CAR-T persistence while mitigating immune rejection.

Extracellular lectins help engineered lymphocytes recognize abnormal glycans when lung tumors lack suitable protein antigens.

Separating Cas9, modified sgRNA, and PUF-effector proteins avoids oversized fusions while enabling multiplexed, orthogonal targeting.

Selected HCDR sequences target CLDN18.2 and CD3 while addressing short half-life and cytokine release risk.

Separate recognition and signaling constructs let CAAR therapies adapt to modified autoantigens and selectively deplete B and T cells.

CMA-targeting signals route peptide-protein complexes to lysosomes for rapid, reversible knockdown of selected endogenous proteins.

Replacing the third extracellular domain in Volvox channelrhodopsin with a Chlamydomonas domain increases ion permeability for optogenetic control.

Modular binding, targeting, and optional release domains address low stability and inefficient non-viral transfection for cell-specific nucleic acid delivery.

Extracellular PSMA targeting uses humanized A5 scFv CARs to improve T-cell activation and cytotoxicity against viable tumor cells.

Proinsulin-specific TCRs direct engineered regulatory T cells toward pancreatic targets, helping suppress autoimmunity and preserve beta cell mass.

Leucine-zipper fragments of CEBPB and CEBPD induce apoptosis in cancer cells while showing minimal impact on normal cells.

Optimized humanized anti-GPC3 binding fragments are integrated into CAR-T cells to target GPC3-positive cancers with stronger tumor killing.

Truncated KL1 polypeptides retain anti-tumor activity while improving recombinant yield for scalable therapeutic production.

Bifunctional fusion proteins link target binding with ubiquitin-proteasome recruitment to remove intracellular proteins that conventional inhibitors leave behind.

Mixed viral vectors pair CAR-encoding sequences with activity modulators to address tumor heterogeneity and improve cell persistence.

Galactose-linked antigen compositions target liver cells to reduce unwanted immune responses and promote tolerization.

Conventional calibrators miss EV-associated ALP; a combined ALP–membrane protein polypeptide improves activity and concentration measurement.

G-CSF-neutralizing antibodies target a cytokine linked to tumor growth and chronic inflammation, supporting cancer and arthritis treatment.

Replacing antibiotic selection proteins, EGFRt retains cetuximab binding for immunomagnetic T-cell enrichment while avoiding immune rejection.

A modified GALV envelope targets SLC20A1, delivering genes to NK cells at up to 90% efficiency while preserving CAR positivity during expansion.

Consensus prME DNA plasmids and electroporation target mammalian cells to induce cellular and humoral immunity across Zika strains.

Multi-antigen VLPs present HCMV gB, gH, and pp65 to trigger neutralizing antibodies and T-cell activation without viral DNA.

Small molecules preserve naïve and memory T-cell states during ex vivo expansion, supporting proliferation, persistence, and cytotoxicity in adoptive therapies.

TSPAN2 scaffolding stabilizes protein-of-interest expression and co-localizes multiple cargos in engineered EVs, including RNA.

First-generation SynNotch receptors face inefficient expression and weak activation; humanized regulators strengthen gene expression in T cells.

CD20 loss in plasma cells limits standard myeloma treatments; FcRH5-binding sdAbs support targeted antibodies, CARs, and immune cell engagers.

Yeast secretion signals combine an αMF leader variant with a non-αMF peptide to raise secreted yields and reduce folding stress.

Engineered Notch receptors use mutant NRRs and cleavable linkers to gate signaling by protease activity for more specific control.

Engineered TCRs use GLNEEIARV and ASSLSGGIYEQY to improve T-cell recognition of NDC80 tumor-specific pMHC complexes.

An engineered SpCas9 tunes PAM-distal guide recognition to distinguish intended targets from partial matches and reduce off-target modifications.

Peripheral- and cord-blood MAIT cells can limit CAR-T efficacy; placental cells engineered with CARs provide stronger lysis and improved survivability.

Engineered CAR cells recognize glycosylated PD-L1 to target cancer cells while limiting normal-cell toxicity and resisting fratricide.

A cleavable peptide keeps anti-CTLA4 binding blocked during circulation until tumor proteases release activity at the tumor site.

Antibody therapies can lose effect against MUC1 cancers; this polypeptide-based CAR activates immune cells for sustained tumor killing.

Selective depletion of CD45RChigh T cells uses anti-human CD45RC binding domains to reduce GvHD without broad immunosuppression.

Targeted OMNI-50 amino acid substitutions reduce off-target editing while maintaining on-target activity for precise genome editing.

A1 and B1 peptides plus ribosome-binding and chaperone elements improve correct αβ-TCR folding and pairing for phage-based mutant screening.

Transmembrane receptor mutations align Janus kinases to strengthen Type III interferon antiviral and antiproliferative signaling with fewer side-effects.

An antibody-free CD27 extracellular-domain CAR equips engineered NK cells to target CD70-positive tumors while addressing prolonged cytopenias.

RNA destabilizing elements and timed CAR expression help NK cells balance tumor surveillance with reduced toxicity and off-target effects.

Specific Cas12i amino acid substitutions improve multiplex editing fidelity while reducing off-target effects in targeted DNA modification.